Muscle wasting with age is one of the most consequential yet underappreciated threats to independent living — and the field has struggled for decades to find a druggable target. A comprehensive review published in the Chinese Medical Journal reframes the problem, arguing that disrupted internal body clocks, not simply anabolic decline, may be a root-cause mechanism driving sarcopenia, opening a new lane for therapeutic development.
The review synthesizes evidence linking dysfunction in core circadian clock genes — including BMAL1, CLOCK, PER, and CRY family members — to three interconnected pathways that govern skeletal muscle integrity: protein remodeling (the balance of synthesis and degradation), insulin signaling and glucose metabolism, and mitochondrial biogenesis and quality control. Critically, it identifies a bidirectional relationship between these clock genes and systemic chronic low-grade inflammation (SCLGI), the smoldering inflammatory state that accelerates with aging. When circadian rhythmicity degrades, inflammatory cytokine profiles worsen; conversely, elevated inflammation further destabilizes clock gene expression — creating a self-reinforcing deterioration cycle. The review also maps external factors — including light exposure timing, meal timing, and physical activity patterns — as levers capable of resynchronizing circadian function.
This framing has genuine translational appeal. Chronobiology's intersection with muscle physiology is relatively new territory, and the absence of any FDA-approved pharmacological treatment for sarcopenia underscores the urgency of fresh mechanistic perspectives. The circadian angle is compelling because it is potentially modifiable through behavioral interventions — time-restricted eating and timed exercise already show preliminary promise in related metabolic contexts. That said, this is a narrative review, not a clinical trial, and the mechanistic links it describes are drawn largely from preclinical models and observational human data. The causal direction between clock disruption and sarcopenia in aging humans remains to be rigorously established. Still, the synthesis is conceptually cohesive and points toward a testable therapeutic hypothesis: that restoring circadian synchrony may simultaneously address both protein dysregulation and inflammaging in aging muscle.
